Adimab LLC’s tech transfer deals with GlaxoSmithKline PLC and Biogen Inc. represent the small biotech’s greatest business development and financial successes to date, and confirm that with the right technology, it’s possible to build a successful and rapidly profitable company whose own ambitions begin and end at drug discovery.
The deals, each announced July 26, see Adimab setting up its technology platform inside its partners’ R&D shops. By licensing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?